Maia Kayal

MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies that exploit telomere biology. The company's lead program, THIO (6-thio-2'-deoxyguanosine), is a first-in-class telomere-targeting agent designed to induce telomerase-dependent telomeric DNA modification and subsequent cancer cell death. MAIA is currently evaluating THIO in Phase 2 clinical trials, particularly in combination with immune checkpoint inhibitors for patients with advanced non-small cell lung cancer. By leveraging the fact that telomerase is overexpressed in the vast majority of human cancers, the company aims to provide a broadly applicable treatment modality for difficult-to-treat malignancies.